2013
DOI: 10.1161/circresaha.111.300271
|View full text |Cite
|
Sign up to set email alerts
|

Historical Lessons in Translational Medicine

Abstract: The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science and sheer luck. The process has evolved as the days of stumbling upon therapeutic gems like aspirin have long passed and have been replaced by an arduous process where a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process. Or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understandi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
21
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 36 publications
(24 citation statements)
references
References 177 publications
1
21
0
Order By: Relevance
“…Notably, considerable individual variability in platelet response and oxylipin production was observed with acute EVOO intake, consistent with variability in other platelet responsive factors (e.g. “aspirin resistance”) which have been postulated to result from differences in metabolism, sex, drug interactions and compliance failure (Fitzgerald & Fitzgerald, 2013; Rocca & Patrono, 2005). Dietary factors may also have played a role, and habitual diet assessments may have aided interpretation of this study.…”
Section: Discussionsupporting
confidence: 64%
“…Notably, considerable individual variability in platelet response and oxylipin production was observed with acute EVOO intake, consistent with variability in other platelet responsive factors (e.g. “aspirin resistance”) which have been postulated to result from differences in metabolism, sex, drug interactions and compliance failure (Fitzgerald & Fitzgerald, 2013; Rocca & Patrono, 2005). Dietary factors may also have played a role, and habitual diet assessments may have aided interpretation of this study.…”
Section: Discussionsupporting
confidence: 64%
“…This was established by seminal work from several laboratories notably those of Vane, Samuelsson, Roth & Majerus, Patrono and FitzGerald 20, 109-115 , and was recently the subject of the 2013 Grand Prix Scientific (Lefoulon-Delalande Foundation, Institute of France) awarded to Garret FitzGerald and Carlo Patrono. More recently, a number of studies found that low dose (considered platelet-selective) aspirin can reduce the spread of existing cancers as well as the risk of developing others, in particular adenocarcinoma of the gut, some lung cancers and breast and prostate cancer.…”
Section: Specific Lipid Families In Plateletsmentioning
confidence: 99%
“…Constitutively expressed COX-1 accounts largely for formation of PGs subserving “housekeeping” functions, such as thromboxane A 2 (TxA 2 ) in hemostasis and PGE 2 and PGI 2 in the maintenance of gastroduodenal epithelial integrity. Platelets express only COX-1, and suppression of platelet COX-1–dependent TxA 2 by low-dose aspirin accounts for its cardioprotective effects (2). COX-2 is more readily regulated in its expression, especially by mitogens and cytokines, and accounts largely for elaboration of the PGE 2 and PGI 2 that mediate pain and inflammation.…”
Section: Introductionmentioning
confidence: 99%